The mouse LD50 was not reported at 150 mg/kg. (Experientia., 20(366), 1964 [PMID:5855670])

MMDA, or 3-methoxy-4,5-methylenedioxyamphetamine, belongs to the amphetamine class of drugs and possesses stimulant and hallucinogenic properties. It is also a hallucinogen and mood enhancer. MMDA is structurally similar to the psychopharmacologically active essential oils elemol and myristole found in nutmeg. MMDA’s effects include euphoria and warmth, as well as realistic visual experiences with eyes closed. Drug Indications MMDA is a recreational drug. Currently, it has no medical use and is classified as a Category 1 controlled substance in the United States. Mechanism of Action The mechanism by which MMDA produces hallucinogenic effects is not fully understood. There are currently no reports on the pharmacokinetics or metabolism of MMDA in humans. Based on its structural relationship with other similar drugs with known pharmacological effects, MMDA may have multiple mechanisms of action, possibly acting as a 5HT2A agonist like hallucinogenic amphetamines such as DOM, or releasing serotonin by reversing the direction of the serotonin reuptake transporter, similar to MDMA.

C11H15NO3

209.105

13674-05-0

60676-84-8 (hydrochloride)

26175

Typically exists as solid at room temperature

1.6

1

4

3

15

212

0

YQYUWUKDEVZFDB-UHFFFAOYSA-N

InChI=1S/C11H15NO3/c1-7(12)3-8-4-9(13-2)11-10(5-8)14-6-15-11/h4-5,7H,3,6,12H2,1-2H3

1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine

3-Methoxy-4,5-methylenedioxyphenylisopropylam; MMDA; 5-Methoxy-3,4-methylenedioxyamphetamine; 13674-05-0; (+-)-MMDA; 3-Methoxy-alpha-methyl-4,5-methylenedioxyphenethylamine; DEA No. 7401; 3-Methoxy-4,5-methylenedioxyphenylisopropylamine; Amphetamine, 3,4-methylenedioxy-5-methoxy; (+-)-MMDA; MMDA

2934.99.9001

Powder      -20°C    3 years

4°C     2 years

In solvent   -80°C    6 months

-20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

 

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)